Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

ASCO and EHA highlights in myeloma and AL amyloidosis

The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual…

Read more

MPE COVID-19 Scholarship Programme

  As part of the work that Myeloma Patients Europe (MPE) is doing to provide members with support during the COVID-19 pandemic, MPE is extending the MPE Scholarship and Capacity Building Programme. Through this extension, MPE will be offering up to 10 scholarships between 2.500 and 5.000€ to develop or adapt programmes or activities related…

Read more

EHA 2020 – Subcutaneous daratumumab shows improved clinical outcomes in AL amyloidosis

New data of the ANDROMEDA clinical trial has been presented today in the late breaking session at the 25th European Hematology Association (EHA) Annual Congress which is happening virtual from 11 to 21 June. This study evaluates subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) compared to CyBorD alone in newly diagnosed patients with AL amyloidosis. Light chain (AL) amyloidosis is…

Read more

FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patients

  Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020.

Read more

New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19

The pharmaceutical company, Karyopharm Therapeutics has announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19 (coronavirus). Selinexor, marketed as XPOVIO®, is currently approved at higher doses by the Food and Drug Administration (FDA) as a treatment for patients with relapsed or refractory multiple myeloma.…

Read more
March

April 2026

May
MO
TU
WE
TH
FR
SA
SU
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
Events for 1st April
No Events
Events for 2nd April
No Events
Events for 3rd April
No Events
Events for 4th April
No Events
Events for 5th April
No Events
Events for 6th April
No Events
Events for 7th April
No Events
Events for 8th April
No Events
Events for 9th April
No Events
Events for 10th April
No Events
Events for 11th April
No Events
Events for 12th April
No Events
Events for 13th April
No Events
Events for 14th April
No Events
Events for 15th April
No Events
Events for 16th April
No Events
Events for 17th April
No Events
Events for 18th April
No Events
Events for 19th April
No Events
Events for 20th April
No Events
Events for 21st April
No Events
Events for 22nd April
No Events
Events for 23rd April
No Events
Events for 24th April
No Events
Events for 25th April
No Events
Events for 26th April
No Events
Events for 27th April
No Events
Events for 28th April
No Events
Events for 29th April
No Events
Events for 30th April
No Events